ReviewThe American journal of the medical sciences2010
Clostridium difficile infection.
Review in The American journal of the medical sciences, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed.
- A first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study to assess the safety and tolerability of LFF571 in healthy volunteers.Antimicrobial agents and chemotherapy · 2012Trial
- Comparison of the LuminexJournal of medical microbiology · 2025Article
- Lipidomics, Microbiota, and IntestinalInternational journal of molecular sciences · 2025Review
- MicroRNA miR-27a-5p Reduces Intestinal Inflammation Induced by Clostridioides difficile Flagella by Regulating the Nuclear Factor-κB Signaling Pathway.The Journal of infectious diseases · 2025Article
- Can Gut Microbiota Analysis RevealMicroorganisms · 2024Article
- A Three-Year Analysis of Mortality in Clostridioides difficile Patients in a Tertiary Center.Cureus · 2024Article
- Phenylthiazoles with potent & optimum selectivity towardRSC medicinal chemistry · 2024Article
- [Analysis ofNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Clostridioides (Clostridium) difficile: A silent nosocomial pathogen.Saudi medical journal · 2023Review
- The Environment, Farm Animals and Foods as Sources ofFoods (Basel, Switzerland) · 2023Article
- Receptor binding mechanisms of Clostridioides difficile toxin B and implications for therapeutics development.The FEBS journal · 2023Review
- Review
- Comparison between Symptomatic and Asymptomatic Mice afterMicroorganisms · 2022Article
- Identification of TFPI as a receptor reveals recombination-driven receptor switching in Clostridioides difficile toxin B variants.Nature communications · 2022Article
- Melatonin as an Antimicrobial Adjuvant and Anti-Inflammatory for the Management of RecurrentAntibiotics (Basel, Switzerland) · 2022Article
- Multi-country surveillance of Clostridioides difficile demonstrates high prevalence of spores in non-healthcare environmental settings.Anaerobe · 2022Article
- About gladiators and a sacred disease.Biomedical journal · 2022Article
- Reduction in Health Care Facility-OnsetMayo Clinic proceedings. Innovations, quality & outcomes · 2021Article
- The Murine Neonatal Fc Receptor Is Required for Transport of Immunization-Induced C. difficile-Specific IgG to the Gut and Protection against Disease but Does Not Affect Disease Susceptibility.Infection and immunity · 2021Article
- Pragmatic Strategy for Fecal Specimen Storage and the Corresponding Test Methods forPathogens (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Clostridium difficile is the leading cause of hospital-acquired diarrhea in Europe and North America and is a serious reemerging pathogen. Recent outbreaks have led to increasing morbidity and mortality and have been associated with a new strain (BI/NAP1/027) of C difficile that produces more toxin than historic strains. With the increasing incidence of C difficile infection, clinicians have also seen a change in the epidemiology with increased infections in previously low-risk populations. This chapter highlights the current knowledge on C difficile virulence, human disease, epidemic outbreaks and optimal treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.